ProductsPricingFree Market DashboardMarket News FeedScannerChartsHeatmapMarket SectorsTrack RecordMAD AcademyMCP Connector

Abivax SA (ABVX)

Nasdaq · American depositary receipt

$93.67+1.08 (+1.16%)

As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.

Follow ABVX in real time

Real-time quotes, Pro Charting, the scanner and the alert feed on ABVX and every other US listing.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Or open the free ABVX chart →

ABVX at a glance

Key statistics

$8.08B

Market capitalization

Previous close
$92.59
Open
$93.92
Day range
$93.33 – $96.25
Volume
629.4K
Average volume (30 sessions)
1.39M
Shares outstanding
87.27M
Beta (1 year, vs SPY)
1.04

Where the price sits in its year

52-week range

30% of the range

Below the 52-week high
-37.1%
Above the 52-week low
+34.2%

Completed sessions through Oct 20, 2026

Technical snapshot

Below its 50-day and 200-day averages

20-day average
$91.42+1.3%
50-day average
$105.34-12.1%
200-day average
$115.35-19.7%
RSI (14)45.7

Between the conventional 30 and 70 bands.

+7.4%

1 week

-10.5%

1 month

-28.6%

3 months

-31.3%

Year to date

-0.2%

1 year

Price change over each window, from completed sessions. Past performance does not indicate future results.

Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.

The member platform, in real time

What members do with ABVX

About Abivax SA

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Exchange
Nasdaq
Security
American depositary receipt
Employees
69
Listed since
Oct 20, 2023
Website
abivax.com
Educational content only. MadStockAlerts provides market commentary, research, and educational content. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security. Trading and investing involve substantial risk, including loss of capital. See the Risk Disclosure and Customer Agreement.

Pick the desk that fits how you trade

Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.